@article{ref1,
title="Managing 5-FluoroUracil induced severe early toxicities: An update on uridine triacetate (Vistogard®)",
journal="Pharmacien Hospitalier et Clinicien",
year="2018",
author="Launay, M. and Pourroy, B. and Ciccolini, J.",
volume="53",
number="4",
pages="354-358",
abstract="For the last 60 years, 5-Fluoro-Uracil (5-FU) ranks among the most widely prescribed anticancer agents worldwide. Standard dosing with 5-FU usually claims 15-40% of severe toxicities, mostly digestive or hematologic disorders. A total of 0.5-3% of toxic deaths are regularly reported. DPD deficiency is often at the origin of the most severe side-effects. Capecitabine is an oral prodrug with the same safety profile. It was involved in suicide attempt or accidental administration to children. Uridine triacetate (Vistogard®) is indicated for the emergency treatment of adult and pediatric patients following an overdose of 5-FU or capecitabine regardless of the presence of symptoms, or who exhibit early onset, severe or life-threatening toxicity and/or early onset, unusually severe adverse reactions. Treatment must be given within 96 hours following the end of 5-FU or capecitabine administration. Survival of patients with 5-FU overdose is improved from 16 to 96%. In France, Vistogard® can be obtained using Temporary Use Authorisation and 12 patients have been administered with uridine triacetate between 2013 and 2015. Hospital pharmacist plays a key role in rescuing patients with 5-FU overdose because the antidote should be administered in the 96 hours following the end of the administration and the treatment shipping and delivery in France takes an average 36 hours. © 2018 Elsevier Masson SAS<p /><p>Language: en</p>",
language="en",
issn="2211-1042",
doi="10.1016/j.phclin.2018.04.004",
url="http://dx.doi.org/10.1016/j.phclin.2018.04.004"
}